Skip to main content

Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.

Publication ,  Conference
Sharib, J; Liu, A; Creasy, J; Wildman-Tobriner, B; Uronis, HE; Strickler, JH; Hsu, DS; Zani, S; Allen, PJ; Lidsky, M
Published in: Journal of Clinical Oncology
February 1, 2022

120 Background: Hepatic artery infusion (HAI) is a liver directed therapy to treat unresectable or resected colorectal liver metastases (CRLM) and unresectable intrahepatic cholangiocarcinoma (ICC). Historically, HAI has only been performed at few specialized centers; however, there is increasing expansion to new centers. We previously reported safety outcomes of our index year of HAI therapy. We now report safety, feasibility, efficacy and oncologic outcomes for an expanded cohort of 62 patients in an established HAI program. Methods: Patients selected for HAI by multidisciplinary review were evaluated for demographics and perioperative outcomes. Objective hepatic response was calculated according to RECIST 1.1. Overall, hepatic and extrahepatic progression-free survival (PFS) were calculated by the Kaplan-Meier method on an intent-to-treat basis. Results: 62 patients were treated with HAI from November 2018-September 2021: 46 for unresectable CRLM, 8 as adjuvant HAI for resected CRLM, and 8 for unresectable ICC. Median age was 54.5 years (range 32-80), 58% were male, and 97% received prior chemotherapy (median 12 cycles, range 0-66). Hepatectomy (18, 29%) and/or colectomy/proctectomy (27, 43.5%) was performed concurrently with pump placement, and 19 (30.6%) were performed robotically. Median operating time was 265 minutes (range 130-526), estimated blood loss was 100 mL (range 22-1000) and length of stay was 5 days (range 1-19). HAI-specific complications occurred in 14% (Table). Floxuridine (FUDR) was initiated in 95% of patients a median of 18.5 days after surgery. Of the 38 patients who received HAI for unresectable CRLM and had measurable disease on imaging, 3- and 6-month hepatic disease control was achieved in 86% (8 partial response [PR], 22 stable disease [SD], 5 progressed [PD]) and 89% (1 complete response, 8 PR, 8 SD, 2 PD), respectively. For patients with at least 3 months follow-up, median PFS, hepatic PFS and extrahepatic PFS were 13 months, 13 months, and 13 months, respectively. Conclusions: HAI can be safely and effectively delivered to well-selected patients with CRLM and ICC. Response rates, disease control and PFS in heavily treated patients with unresectable CRLM comparable to high-volume centers can be achieved at new programs with appropriate expertise. These data support the mission of the newly formed HAI Consortium to critically evaluate efficacy and innovation in HAI therapy through multi-institutional collaboration and contemporary prospective trials.[Table: see text]

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 1, 2022

Volume

40

Issue

4_suppl

Start / End Page

120 / 120

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sharib, J., Liu, A., Creasy, J., Wildman-Tobriner, B., Uronis, H. E., Strickler, J. H., … Lidsky, M. (2022). Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program. In Journal of Clinical Oncology (Vol. 40, pp. 120–120). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2022.40.4_suppl.120
Sharib, Jeremy, Annie Liu, John Creasy, Benjamin Wildman-Tobriner, Hope Elizabeth Uronis, John H. Strickler, David S. Hsu, Sabino Zani, Peter J. Allen, and Michael Lidsky. “Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.” In Journal of Clinical Oncology, 40:120–120. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.4_suppl.120.
Sharib J, Liu A, Creasy J, Wildman-Tobriner B, Uronis HE, Strickler JH, et al. Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 120–120.
Sharib, Jeremy, et al. “Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.Journal of Clinical Oncology, vol. 40, no. 4_suppl, American Society of Clinical Oncology (ASCO), 2022, pp. 120–120. Crossref, doi:10.1200/jco.2022.40.4_suppl.120.
Sharib J, Liu A, Creasy J, Wildman-Tobriner B, Uronis HE, Strickler JH, Hsu DS, Zani S, Allen PJ, Lidsky M. Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 120–120.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 1, 2022

Volume

40

Issue

4_suppl

Start / End Page

120 / 120

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences